|
1
|
Socinski MA: Cytotoxic chemotherapy in
advanced non-small cell lung cancer: A review of standard treatment
paradigms. Clin Cancer Res. 10:4210s–4214s. 2004.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Garassino MC, Gadgeel S, Speranza G, Felip
E, Esteban E, Dómine M, Hochmair MJ, Powell SF, Bischoff HG, Peled
N, et al: Pembrolizumab plus pemetrexed and platinum in nonsquamous
non-small-cell lung cancer: 5-Year outcomes from the phase 3
KEYNOTE-189 study. J Clin Oncol. 41:1992–1998. 2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Minoo P, Su G, Drum H, Bringas P and
Kimura S: Defects in tracheoesophageal and lung morphogenesis in
Nkx2.1(-/-) mouse embryos. Dev Biol. 209:60–71. 1999.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Hosono Y, Yamaguchi T, Mizutani E,
Yanagisawa K, Arima C, Tomida S, Shimada Y, Hiraoka M, Kato S,
Yokoi K, et al: MYBPH, a transcriptional target of TTF-1, inhibits
ROCK1, and reduces cell motility and metastasis. EMBO J.
31:481–493. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hwang DH, Sholl LM, Rojas-Rudilla V, Hall
DL, Shivdasani P, Garcia EP, MacConaill LE, Vivero M, Hornick JL,
Kuo FC, et al: KRAS and NKX2-1 mutations in invasive mucinous
adenocarcinoma of the lung. J Thorac Oncol. 11:496–503.
2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Matsubara D, Soda M, Yoshimoto T, Amano Y,
Sakuma Y, Yamato A, Ueno T, Kojima S, Shibano T, Hosono Y, et al:
Inactivating mutations and hypermethylation of the NKX2-1/TTF-1
gene in non-terminal respiratory unit-type lung adenocarcinomas.
Cancer Sci. 108:1888–1896. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Maeda Y, Tsuchiya T, Hao H, Tompkins DH,
Xu Y, Mucenski ML, Du L, Keiser AR, Fukazawa T, Naomoto Y, et al:
Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous
adenocarcinoma of the lung. J Clin Invest. 122:4388–4400.
2012.PubMed/NCBI View
Article : Google Scholar
|
|
9
|
Snyder EL, Watanabe H, Magendantz M,
Hoersch S, Chen TA, Wang DG, Crowley D, Whittaker CA, Meyerson M,
Kimura S and Jacks T: Nkx2-1 represses a latent gastric
differentiation program in lung adenocarcinoma. Mol Cell.
50:185–199. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Barletta JA, Perner S, Iafrate AJ, Yeap
BY, Weir BA, Johnson LA, Johnson BE, Meyerson M, Rubin MA, Travis
WD, et al: Clinical significance of TTF-1 protein expression and
TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med.
13:1977–1986. 2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chung KP, Huang YT, Chang YL, Yu CJ, Yang
CH, Chang YC, Shih JY and Yang PC: Clinical significance of thyroid
transcription factor-1 in advanced lung adenocarcinoma under
epidermal growth factor receptor tyrosine kinase inhibitor
treatment. Chest. 141:420–428. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Nishioka N, Hata T, Yamada T, Goto Y,
Amano A, Negi Y, Watanabe S, Furuya N, Oba T, Ikoma T, et al:
Impact of TTF-1 expression on the prognostic prediction of patients
with non-small cell lung cancer with PD-L1 expression levels of 1%
to 49%, treated with chemotherapy vs chemoimmunotherapy: A
multicenter, retrospective study. Cancer Res Treat. 57:412–421.
2025.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ibusuki R, Yoneshima Y, Hashisako M,
Matsuo N, Harada T, Tsuchiya-Kawano Y, Kishimoto J, Ota K,
Shiraishi Y, Iwama E, et al: Association of thyroid transcription
factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors
plus pemetrexed and platinum chemotherapy in advanced non-squamous
non-small cell lung cancer. Transl Lung Cancer Res. 11:2208–2215.
2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Nakahama K, Kaneda H, Osawa M, Izumi M,
Yoshimoto N, Sugimoto A, Nagamine H, Ogawa K, Matsumoto Y, Sawa K,
et al: Association of thyroid transcription factor-1 with the
efficacy of immune-checkpoint inhibitors in patients with advanced
lung adenocarcinoma. Thorac Cancer. 13:2309–2317. 2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Katayama Y, Yamada T, Morimoto K, Fujii H,
Morita S, Tanimura K, Takeda T, Okada A, Shiotsu S, Chihara Y, et
al: TTF-1 expression and clinical outcomes of combined
chemoimmunotherapy in patients with advanced lung adenocarcinoma: A
prospective observational study. JTO Clin Res Rep.
4(100494)2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Terashima Y, Matsumoto M, Iida H,
Takashima S, Fukuizumi A, Takeuchi S, Miyanaga A, Terasaki Y,
Kasahara K and Seike M: Predictive impact of diffuse positivity for
TTF-1 expression in patients treated with platinum-doublet
chemotherapy plus immune checkpoint inhibitors for advanced
nonsquamous NSCLC. JTO Clin Res Rep. 4(100578)2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Uhlenbruch M and Krüger S: Effect of TTF-1
expression on progression free survival of immunotherapy and
chemo-/immunotherapy in patients with non-small cell lung cancer. J
Cancer Res Clin Oncol. 150(394)2024.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Iso H, Hisakane K, Mikami E, Suzuki T,
Matsuki S, Atsumi K, Nagata K, Seike M and Hirose T: Thyroid
transcription factor-1 (TTF-1) expression and the efficacy of
combination therapy with immune checkpoint inhibitors and cytotoxic
chemotherapy in non-squamous non-small cell lung cancer. Transl
Lung Cancer Res. 12:1850–1861. 2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Nishioka N, Kawachi H, Yamada T, Tamiya M,
Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, et al:
Unraveling the influence of TTF-1 expression on immunotherapy
outcomes in PD-L1-high non-squamous NSCLC: A retrospective
multicenter study. Front Immunol. 15(1399889)2024.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Vidarsdottir H, Tran L, Nodin B, Jirström
K, Planck M, Mattsson JSM, Botling J, Micke P, Jönsson P and
Brunnström H: Comparison of three different TTF-1 clones in
resected primary lung cancer and epithelial pulmonary metastases.
Am J Clin Pathol. 150:533–544. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Cardnell RJG, Behrens C, Diao L, Fan Y,
Tang X, Tong P, Minna JD, Mills GB, Heymach JV, Wistuba II, et al:
An integrated molecular analysis of lung adenocarcinomas identifies
potential therapeutic targets among TTF1-negative tumors, including
DNA repair proteins and Nrf2. Clin Cancer Res. 21:3480–3491.
2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Prelaj A, Tay R, Ferrara R, Chaput N,
Besse B and Califano R: Predictive biomarkers of response for
immune checkpoint inhibitors in non-small-cell lung cancer. Eur J
Cancer. 106:144–159. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Turner BM, Cagle PT, Sainz IM, Fukuoka J,
Shen SS and Jagirdar J: Napsin A, a new marker for lung
adenocarcinoma, is complementary and more sensitive and specific
than thyroid transcription factor 1 in the differential diagnosis
of primary pulmonary carcinoma: Evaluation of 1674 cases by tissue
microarray. Arch Pathol Lab Med. 136:163–171. 2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
El Hag M, Schmidt L, Roh M and Michael CW:
Utility of TTF-1 and Napsin-A in the work-up of malignant
effusions. Diagn Cytopathol. 44:299–304. 2016.PubMed/NCBI View
Article : Google Scholar
|
